Find here a listing of the latest industry news in genomics, genetics, precision medicine, and beyond. Updates are provided on a monthly basis. Sign-Up for our newsletter and never miss out on the latest news and updates. As 2019 came to an end, Veritas Genetics struggled to get funding due to concerns it had previously taken money from China. It was forced to cease US operations and is in talks with potential buyers. The GenomeAsia 100K Project announced its pilot phase with hopes to tackle the underrepresentation of non-Europeans in human genetic studies and enable genetic discoveries across Asia. Veritas Genetics, the start-up that can sequence a human genome for less than $600, ceases US operations and is in talks with potential buyers Veritas Genetics ceases US operations but will continue Veritas Europe and Latin America. It had trouble raising funding due to previous China investments and is looking to be acquired. Illumina loses DNA sequencing patents The European Patent ...
Alphabet is using its dominance in the search and advertising spaces -- and its massive size -- to find its next billion-dollar business. From healthcare to smart cities to banking, here are 10 industries the tech giant is targeting. With growing threats from its big tech peers Microsoft, Apple, and Amazon, Alphabet's drive to disrupt has become more urgent than ever before. The conglomerate is leveraging the power of its first moats -- search and advertising -- and its massive scale to find its next billion-dollar businesses. To protect its current profits and grow more broadly, Alphabet is edging its way into industries adjacent to the ones where it has already found success and entering new spaces entirely to find opportunities for disruption. Evidence of Alphabet's efforts is showing up in several major industries. For example, the company is using artificial intelligence to understand the causes of diseases like diabetes and cancer and how to treat them. Those learnings feed into community health projects that serve the public, and also help Alphabet's effort to build smart cities. Elsewhere, Alphabet is using its scale to build a better virtual assistant and own the consumer electronics software layer. It's also leveraging that scale to build a new kind of Google Pay-operated checking account. In this report, we examine how Alphabet and its subsidiaries are currently working to disrupt 10 major industries -- from electronics to healthcare to transportation to banking -- and what else might be on the horizon. Within the world of consumer electronics, Alphabet has already found dominance with one product: Android. Mobile operating system market share globally is controlled by the Linux-based OS that Google acquired in 2005 to fend off Microsoft and Windows Mobile. Today, however, Alphabet's consumer electronics strategy is being driven by its work in artificial intelligence. Google is building some of its own hardware under the Made by Google line -- including the Pixel smartphone, the Chromebook, and the Google Home -- but the company is doing more important work on hardware-agnostic software products like Google Assistant (which is even available on iOS).
These authors contributed equally to this work. Artificial intelligence (AI) researchers claim that they have made great'achievements' in clinical realms. However, clinicians point out the so-called'achievements' have no ability to implement into natural clinical settings. The root cause for this huge gap is that many essential features of natural clinical tasks are overlooked by AI system developers without medical background. In this paper, we propose that the clinical benchmark suite is a novel and promising direction to capture the essential features of the real-world clinical tasks, hence qualifies itself for guiding the development of AI systems, promoting the implementation of AI in real-world clinical practice. AI researchers claim that they have obtained many significant'achievements' in various However, in practice, most of the AI products fail to obtain approval from the Food and Drug Administration (FDA). AI devices are not qualified handling high-risk tasks such as clinical diagnosis .